Novo Nordisk
↗Bagsværd, Denmark
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. It is a world leader in diabetes care and has rapidly expanded into a dominant position in the obesity market through its blockbuster GLP-1 therapies, Ozempic and Wegovy. The company also maintains a strong presence in rare blood disorders (hemophilia) and endocrine disorders.
Controlled by the Novo Nordisk Foundation through Novo Holdings A/S, the company operates with a long-term focus on chronic disease management. In recent years, it has become the most valuable company in Europe by market capitalization, driven by the unprecedented demand for its weight-loss medications and its expansion into cardiovascular and metabolic health.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Metabolic and Rare Disease Therapeutics
SIZE & FINANCIALS
Employees:10000+
Revenue:$42B-$47B
Founded:1923
Ownership:public
Status:operating
FUNDING
Stage:Public
Investors:Novo Holdings A/S (Majority Shareholder)
STOCK
Exchange:Nasdaq Copenhagen / NYSE
Ticker:NOVO B / NVO
Market Cap:$550B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Semaglutide)
Modalities:Peptides, Small molecule, mAb, RNAi, Cell therapy
Active Trials:150
Trial Phases:Phase 1: 35 | Phase 2: 45 | Phase 3: 40 | Phase 4: 30
FDA Approvals:45
EMA Approvals:42
CORPORATE STRUCTURE
Parent Company:Novo Holdings A/S
Subsidiaries:Dicerna Pharmaceuticals, Forma Therapeutics, Cardior Pharmaceuticals, Akero Therapeutics
Key Partnerships:Omega Therapeutics (Cardiometabolic), Korro Bio (RNA editing), Flagship Pioneering (Obesity)
COMPETITION
Position:Leader
Competitors:Eli Lilly, Sanofi, AstraZeneca, Amgen, Viking Therapeutics
LEADERSHIP
Key Executives:
Maziar Mike Doustdar - CEO (as of Aug 2025)
Lars Fruergaard Jørgensen - Former CEO / Executive
Martin Holst Lange - EVP, Development
Scientific Founders:August Krogh, Marie Krogh
Board Members:Helge Lund (Chair), Henrik Poulsen, Andreas Fibig
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Novo Nordisk and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Novo Nordisk. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.